Aptar Pharma is announce that its innovative, preservative-free multidose Ophthalmic Squeeze Dispenser has been approved for Santen’s prescription drug Taflotan®/Saflutan® for the reduction of elevated intraocular pressure (IOP) in open angle glaucoma and ocular hypertension in 26 countries in Europe.
This approval reconfirms the market-leading position of Aptar Pharma’s Ophthalmic Squeeze Dispenser as an approved delivery system for eye disease treatment formulations without any preservatives.
Aptar Pharma is working closely with leading global ophthalmology specialist Santen Pharmaceutical Co., Ltd. to improve patient safety, achieve dosing accuracy and maintain product integrity.
Aptar Pharma’s Ophthalmic Squeeze Dispenser provides a unique competitive advantage by addressing the worldwide trend towards patient-friendly, cost-effective and preservative-free multidose dispensers, and has over 175 commercial references on the market worldwide.
It is the result of more than 10 years of development and experience in the delivery of preservative-free ophthalmic solutions.
Patients and consumers in the U.S., Europe, Latin America and Asia have benefited from this technology since 2012, with more than 175 commercial references now available on the market.
“Our Ophthalmic Dispenser technology has been a great success for our customers,” explained Matthias Birkhoff, vice president business development, Aptar Pharma. “The proven and unrivalled microbiological safety, combined with a precise and reproducible drop ejection, allows pharmaceutical customers worldwide to enter into discussions with regulatory agencies such as the German BfArM with confidence.”
Mr. Birkhoff also pointed out the user-friendliness of the system, adding: “The ergonomic, pocket-size design and the intuitiveness of a squeezable container with a low actuation force certainly contribute to the high levels of acceptance among patients and consumers worldwide.”